Does oxidative stress participate in nerve cell death in parkinson's disease?

European Neurology

Volumn 33, Issue , 1993, Pages 52-59

  Hirsch, E C ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Calcium; Cell death; Free radicals; Parkinson s disease; Substantia nigra

Indexed keywords

CALCIUM; CATECHOLAMINE; FREE RADICAL; GLUTATHIONE PEROXIDASE; IRON; NEUROMELANIN;

AUTOOXIDATION; CATECHOLAMINE NERVE CELL; CONFERENCE PAPER; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; HUMAN; LIPID PEROXIDATION; MESENCEPHALON; NERVE CELL NECROSIS; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

CALCIUM; CORPUS STRIATUM; DOPAMINE; FREE RADICALS; HUMAN; MESENCEPHALON; NERVE DEGENERATION; PARKINSON DISEASE; REACTIVE OXYGEN SPECIES; RECEPTORS, DOPAMINE; SUBSTANTIA NIGRA;

EID: 0027265699     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000118538     Document Type: Article

References (63)

1. Ehringer H, Hornykiewicz O: Vertcilung von Noradrenalin und Dopamin (3-hydroxytyramin) in Gchirn des Menschen und ihr Verhalten bei Erkrankungen des Extrapyramidalen Systems. Klin Wochenschr 1960;38:1236-1239.
2. Hirsch EC, Graybiel AM, Agid Y: Melanized dopaminergic neurons are differentially affected in Parkinson’s disease. Nature 1988; 334:345-348.
3. Hirsch EC, Mouatt A, Faucheux B, Bonnet AM, Javoy-Agid F, Graybiel AM, Agid Y: Dopamine tremor and Parkinson’s disease. Lancet 1992:340:125-126.
4. Forno LS: Pathology of Parkinson’s disease: in Marsden CD, Fahn S (eds): Movement Disorders. London, Butterworths, 1982, pp 25-40.
5. Cash R, Dennis T, Lheureux R, Raisman R, Javoy-Agid F, Scalton B: Parkinson’s disease and dementia: Norepinephrine and dopamine in locus coerulcus. Neurology 1987;37:42-46.
6. Malessa S, Hirsch EC, Cervera P, Duyckaerts C, Agid Y: Catecholaminergic systems in the medulla oblongata in parkinsonian syndroms. Neurology 1990;40:1739-1743.
7. Jellinger K: The pathology of parkinsonism; in Marsden CD, Fahn S (eds): Movement Disorders. 2. International Medical Reviews. Neurology. London. Butterworths. vol 7, pp 1987. 124-165.
8. Whitchousc PJ, Hedreen JC, White CL, Price DL: Basal forebrain neurons in the dementia of Parkinson’s disease. Ann Neurol 1983;13:243-248.
9. Arendt T, Bigl V, Arendt A, Tennstedt A: Loss of neurons in the nucleus basalis of Meynert in Alzheimer’s disease, paralysis agitans and Korsakoff’s disease. Acta Neurophathol Berl 1983; 61:101-108.
10. Gaspar P, Gray F: Dementia in idiopathic Parkinson’s disease: A neuropathological study on 32 cases. Acta Neuropathol 1984;64:43-53.
11. Tagliavini F, Pilleri G, Bouras G, Constantidinis J: The basal nucleus of Meynert in idiopathic Parkinson’s disease. Acta Neurol Scand 1984;69:20-28.
12. Jellinger K: Pathology of parkinsonism: in Fahn S, Marsden CD, Jenner P, Teychenne P (eds): Recent Developments in Parkinsons’ Disease. New York, Raven Press. 1986, pp 33-66.
13. Hirsch E, Graybiel AM, Duyckaerts C, Javoy-Agid F: Neuronal loss in the pedunculopontine tegmental nucleus in Parkinson’s disease and in progressive supranuclear palsy. Proc Natl Acad Sci 1987;84:5976-5980.
14. Zweig RM, Whitehouse PJ, Casanova MF, Walker LC, Jankel WR, Price DL: Loss of pedunculopontine neurons in progressive supranuclear palsy. Ann Neurol 1987;22:18-25.
15. Jellinger K: The pedunculopontine nucleus in Parkinson’s disease, progressive supranuclear palsy and Alzheimer’s disease. J Neurol Neurosurg Psychiatry 1988;51:540-543.
16. Studlcr JM, Javoy-Agid F, Cessclin F, Legrand JC, Agid Y: CCK-8 immunoreactivity distribution in human brain: selective decrease in the substantia nigra from parkinsonian patients. Brain Res 1982;243:176-179.
17. Taquet H, Javoy-Agid F, Ccsselin F, Hamon M, Legrand JC, Agid Y: Microtopography of methionine-enkcphalin. dopamine and noradrenaline in the ventral mesencephalon of human control and parkinsonian brains. Brain Res 1982;235:303-314.
18. Mauborgne A, Javoy-Agid F, Legrand JC, Agid Y, Cesselin F: Decrease of substance P-like immunoreactivity in the substantia nigra and pallidum of parkinsonian brains. Brain Res 1983;268:167-170.
19. Tenovuo O, Rinne UK, Viljanen MK: Substance P immunoreactivity in the postmortem parkinsonian brain. Brain Res 1984;303:113-116.
20. Villares J, Faucheux B, Strada O, Hirsch EC, Agid Y, Javoy-Agid F: Autoradiographic study of [125l]epidermal growth factor binding sites in the mesencephalon of control and parkinsonian brains postmortem. Brain Res, submitted.
21. Langston JW, Ballard P, Tetrud JW, Irwin I: Chronic parkinsonism in humans due to a product of mepedrine analogue synthesis. Science 1983;219:979-980.
22. Dexter DT, Carter CJ, Wells FR, Javoy-Agid F, Agid Y, Lees A, Jenner P, Marsden CD: Basal lipid peroxidation in substantia nigra is increased in Parkinson’s disease. J Neurochem 1989;52:381-389.
23. Mann DMA, Yates PO: Possible role of neuromelanin in the pathogenesis of Parkinson’s disease. Mech Ageing Dev 1983;21:193-203.
24. Kastner A, Hirsch EC, Lejeune O, Javoy-Agid F, Agid Y: Is the vulnerability of neurons in the substantia nigra of patients with Parkinson’s disease related to their neuromelanin content? J Neurochem 1992;59:1080-1089.
25. D’Amato RJ, Benham DF, Snyder S: Characterization of the bindingof N-methyl-4-phenylpyridine, the toxic metabolite of the parkinsonian neurotoxin N-methyl-4-phenyl-1, 2, 3, 6-tetrahydopyridine to neuromelanin. J Neurochem 1987;48:653-658.
26. Swartz HM, Sarna T, Zecca L: Modulation by neuromelanin of the availability and reactivity of metal ions. Ann Neurol 1992;32:S69-S75.
27. Ambani LM, Van Voert MH, Murphy S: Brain peroxidase and calalase in parkinson’s disease. Arch Neurol I975;32:l 14-118.
28. Perry TL, Godin DV, Hansen S: Parkinson’s disease: A disorder due to nigral glutathione deficiency? Neurosci Lett 1982;33:305-310.
29. Ceballos I, Lafon M, Javoy-Agid F, Hirsch E, Nicole A, Sinet PM, Agid Y: Superoxide dismutase and Parkinson’s disease. Lancet 1990; 335:1035-1036.
30. Damier P, Hirsch E, Javoy-Agid F, Zhang P, Agid Y: Glutathione peroxidase, glial cells and Parkinson’s disease. Neuroscience. 1993:52: 1-6.
31. Youdm MBH, Bcn-Shachar D, Riederer P: The role of monoamine oxidase, iron-melanin interactions, and intracellular calcium in Parkinson’s disease. J Neural Trans 1990;32 (suppl):239-248.
32. Earle KM: Studies in Parkinson’s disease including x-ray fluorescent spectroscopy of formalin fixed tissue. J Neuropathol Exp Neurol 1968;27:1-14.
33. Dexter DT, Wells FR, Lees AJ, Agid F, Agid Y, Jenner P, Marsden CD: Increased nigral iron content and alterations in other metal ions occuring in brain in Parkinson’s disease. J Neurochem 1989;52:1830-1836.
34. Jellinger K, Paulus W, Grundke-lqbal I: Brain iron and ferritin in Parkinson’s and Alzheimer’s diseases. J Neural Transm 1990;2:327-340.
35. Jellinger K, Kienzl E, Paulus W, Riederer P, Rumpelmair H, Sofic E: Iron and ferritin in substantia nigra in Parkinson’s disease; in Narabayashi H, Nagastu T, Yanagisawa N, Mizuno Y (eds): Parkinson’s Disease: From Basic Research to Treatment. Raven Press, New York. 1993, pp 267-281.
36. Hirsch EC, Brandel JP, Gallc P, Javoy-Agid F, Agid Y: Iron and aluminum increase in the substantia nigra of patients with Parkinson’s disease: An x-ray microanalysis. J Neurochem 1991;56:446-451.
37. Perl DP, Good PF, Olanow CW: Cellular distribution of iron in Parkinson’s disease. Ml Sinai J Med 1992: in press.
38. Gulteridge JM, Quilan GJ, Clark I, Halliwel B: Aluminium salts accelerate peroxidation of membrane lipids stimulated iron salts. Biochim Biophys Acta 1985;835:441-447.
39. Shapira AHV, Mann VM, Cooper JM, Dexter D, Daniel SE, Jenner P, Clark JB, Marsden CD: Anatomical and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson’s disease. J Neurochem 1990;55: 2142-2149.
40. Farber JL, Chien KR, Mittnacht S Jr: The pathogenesis of irreversible cell injury in ischemia. Am J Pathol 1991;102:271-281.
41. Mayer ML, Westbrook GL: Cellular mechanisms underlying excitotoxicity. Trends Neurosci 1987;10:59-61.
42. Rothman SM, Olney JW: Excitotoxicity and NMDA receptors. Trends Neurosci 1987;10: 299-302.
43. Yamsda T, Me Geer PL, Baintbridge KG, Me Geer P: Relative sparing in Parkinson’s disease of substantia nigra dopamine neurons containing calbindin D28k. Brain Res 1990;526:303-307.
44. German DC, Manaye KF, Brown J, Gerfen CR: Calcium-binding protein immunoreactivity in the human midbrain: Relationship to dopaminergic neurons. Soc Neurosci Abstr 1990;16:696.
45. Manaye KF, Sonsalla PK, Brooks BA, German DC: Calbindin-28k is located in the midbrain dopaminergic neurons which are resistant to MPTP-induccd degeneration. Soc Neurosci Abstr 1991;17:1275.
46. Lavoie B, Parent A: relative sparing of dopaminergic neurons containing calbindin-28K in parkinsonian monkey. Soc Neurosci Abstr 1991;17:143.
47. Hirsch EC, Mouatl A, Thomassct M, Javoy-Agid F, Agid Y, Graybicl AM: Expression of calbindin D28k-Like immunoreactivity in catecholaminergic cell groups of the human midbrain: Normal distribution and distribution in Parkinson’s disease. Neurodcgeneration 1992;1:83-93.
48. Rydel RE, Greene LA: Acidic and basic fibroblast growth factors promote stable neurite outgrowth and neuronal differentiation in culture ofPCIIcells.J Neurosci 1987;7:3639-3653.
49. Claude P, Parada IM, Gordon KA, D’Amore PA, Wagner JA: Acidic fibroblast growth factor stimulates adrenal chromaffin cells to proliferate and to extend neuritcs. but is not long-term survival factor. Neuron 1988:1:783-790.
50. Ferrari G, Minozji M-C, Toffano G: Basic fibroblast growth factor promotes the survival and development of mesencephalic neurons in culture. Dev Biol 1989;133:140-147.
51. Matsuda S, Saito H, Nishiyama N: Effect of basic fibroblast growth factor on neurons cultured from various regions of postnatal rat brain. Brain Res 1990;529:310-316.
52. Kniissel B, Michel PP, Schwaber JS, Hefti F: Selective and nonselective stimulation of central cholinergic and dopaminergic development in vitro by nerve growth factor, basic fibroblast growth factor, epidermal grow th factor. insulin and insulin-like growth factors I and II, J Neurosci 1990;10:558-570.
53. Date I, Notter MFD, Feltcn SY, Fcllen DL: MPTP-treated young mice but not aging mice show partial recovery of ihe nigrostriatal dopaminergic system by strereotaxic injection of acidic fibroblast growth factor (aFGE). Brain Res 1990;526:156-160.
54. Otto D, Unsicker K: Basic FGF reverses chemical and morphological deficits in the nigrostriatal system of MPTP-treated mice. J Neurosci 1990;10:1912-1921.
55. Bean AJ, Elde R, Cao Y, Oellig C, Tamminga C, Goldstein M, Pettersson RF, Hokfclt T, Expression of acidic and basic fibroblast growth factors in the substantia nigra of rat. monkey and human. Proc Natl Acad Sci USA, 1991;.88:10237-10241.
56. Hofer MM, Barde YA: Brain-derived ncurotrophie factor prevents neuronal death in vivo. Nature 1988;331:261-265.
57. Hyman C, Hofer M, Barde YA, Juhasz M, Yancopoulos GD, Squinto SP, Lindsay RM: BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 1991;350:230-232.
58. Goodman R, Slater E, Herschman HR: Epidermal growth factor induces tyrosine hydroxylase in clonal phcochromocytoma cell line PC-G2. J Cell Biol 1980;84:495-500.
59. Fallon JH, Serrogy KB, Loughlin SE, Morrison RS, Bradshaw RA, Knauer DJ, Cunningham DD: Epidermal growth factor immunoreactivc material in the central nervous system location and development. Science 1984;224:1107-1109.
60. Lewis EJ, Chikaraishi DM: Regulated expression cf tyrosine hydroxylase gene by epidermal growth factor. Mol Cell Biol 1987;7:3332-3336.
61. Lov R, Hcyer D, DiStefano P: Sensitivity of substantia nigra neurons to epidermal growth factor. Soc Neurosci Abstr 1988;14:302.
62. Casper D, Blum M, Mytilineou C: Epidermal growth factor is neurotrophic in rat embryo mesencephalic primary culture. Soc Neurosci Abstr 1989;15:708.
63. Casper D, Mytilineou C, Blum M: Epidermal growth factor is a mitogen and increases dopamine uptake in rat embryo mesencephalic pri mary culture. Soc Neurosci Abstr 1990;16: 999.